Squarepoint
IMRX icon

Squarepoint’s Immuneering IMRX Stock Holding History

Squarepoint’s Portfolio IMRX Stock Details IMRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.19M Buy
226,046
+133,790
+145% +$686K ﹤0.01% 2626
2025
Q4 		$607K Buy
+92,256
New +$592K ﹤0.01% 3054
2024
Q3 		– Sell
-24,262
Closed -$31.1K – 4370
2024
Q2 		$31.1K Buy
+24,262
New +$39.9K ﹤0.01% 3941

Other funds holding IMRX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
S
Sanofi Paris, France $336M AUM 126.85% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
OCM
Occam Crest Management Darien, Connecticut $165M AUM
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Squarepoint's IMRX Position: Q1 2026 in Review

Squarepoint increased its Immuneering (IMRX) stake by 145% in Q1 2026, buying an estimated $686K and bringing the position to 226,046 shares worth $1.19M. The position accounts for ﹤0.01% of the portfolio, ranked #2626.

Squarepoint first reported a position in IMRX in Q2 2024 and has held it in 3 quarters since. 95 funds tracked by Wall St. Rank hold IMRX as of Q1 2026.

  • Squarepoint held 226,046 shares of Immuneering worth $1.19M as of Q1 2026.
  • Squarepoint bought 133,790 Immuneering shares in Q1 2026, an estimated $686K.
  • Immuneering made up ﹤0.01% of Squarepoint's portfolio in Q1 2026, its #2626 holding.
  • Squarepoint first reported a position in Immuneering in Q2 2024 and has held it in 3 quarters since.
  • 95 funds tracked by Wall St. Rank held Immuneering as of Q1 2026.

Based on Squarepoint's 13F filing for Q1 2026, filed 15 May 2026.